BIO Week 2026 Roster
Calvin Carter | invizix
Invizix is building a sleep-time bioelectronic platform that programs metabolism to treat diseases driven by metabolic dysfunction. Think of it as a remote control for metabolism. Our initial focus is diabetes, where we use electromagnetic fields to improve glucose handling and insulin sensitivity, with a parallel glioblastoma program aimed at disrupting tumor metabolism. Our mission is to make medicine invisible by creating therapies that work in the background while patients live and sleep.
Paul Christie | Tachmed
Tachmed develops advanced medical technologies designed to improve procedural precision and patient outcomes. By combining innovative engineering with practical clinical insights, it offers solutions that enhance efficiency, reduce variability, and elevate standards of care.
David Larwood | MycaZED
MycaZED is advancing a targeted therapy designed to treat fungal infections more effectively to deliver safer and more consistent outcomes for patients. Powered by a novel antifungal mechanism, it seeks to replace today’s limited treatment options that can be toxic, prolonged, and often ineffective.
Casey McPherson | AlphaRose Therapeutics
AlphaRose Therapeutics is building a new model for developing and delivering genetic medicines at scale, focused on children with rare genetic diseases. The company combines advanced genetic technologies with a patient-centric, vertically integrated approach to rapidly create and commercialize treatments that traditional pharma models often overlook due to small patient populations.
Cody Rasmussen-Ivey | Galvanis
Galvanis is building wound-healing drugs, starting with eye drops for corneal wounds. Its lead program, OcuRegen™, is designed to move care from passive protection to active closure by targeting the cornea’s endogenous bioelectric repair biology. The first indication is persistent corneal epithelial defects.
Arun Singh | FlexiGrace Bio
FlexiGrace Bio gently separates cells from tissue, delivering cleaner isolation and consistently superior results. Powered by Feather technology, it replaces today’s harsh and imprecise tissue and cell separation methods that often damage samples and compromise outcomes.
“One of the greatest strengths of this program was the people. The coaches never held back in their input, and that honesty and candor were a major plus. Beyond that, so many other members also stepped in to support and guide me throughout—reminding me that this truly is a community built on collective success.”
— Chandi Bandara, Money Ball BIO 2025 Player, CEO, Precision Quantomics
“Very valuable and helpful. It provided some real world feedback and some great connections for us moving forward. Coaches are awesome and do a nice job of guidance and discussion as we refined our message.”
— Doug Cohen, Money Ball BIO 2025 Player, CEO, IR Medtek
“The respect, collaboration and support that the BLPN team engenders - even when many balls are in the air and adjustments are being made - that's what makes this an incredible experience and worth the time and effort. So a big, heart-felt THANK YOU!”
— Michael Hill, Money Ball BIO 2025 Head Coach, Co-Founder of Science Innovations, LLC
“From my perspective as Head Coach, the real value of the Money Ball program is that it takes brilliant founders and gives them the structure, discipline, and confidence to step into the investor arena. Founders often start with powerful science but without a clear commercial identity or investor-ready story. Money Ball closes that gap. It equips CEOs with the tools—licensing strategy, valuation benchmarks, pitch discipline, and clear milestones—that transform an early-stage idea into a fundable company. . . .”
— Stella Vnook, Head Coach for BIO 2025, Founder of Agile Consulting Group